USPSTF: More data needed on e-cigarette effectiveness as cessation aid

USPSTF: Not Enough Data on E-Cigarettes As Cessation Aid
USPSTF: Not Enough Data on E-Cigarettes As Cessation Aid

(HealthDay News) -- There's not enough data to decide whether or not electronic cigarettes can help smokers quit, according to the U.S. Preventive Services Task Force (USPSTF).

E-cigarette use is continuing to boom in popularity across the United States, and some proponents of the device say it provides a safer alternative to cigarettes and a potential bridge to quitting. However, the USPSTF said there simply isn't enough good research for the panel to make a decision about whether e-cigarettes are a good idea for adults who wish to stop smoking.

The USPSTF recommends behavioral therapy and federally approved medications, such as nicotine replacement treatments, for most adults who want to stop smoking. The exception: pregnant women. For them, the task force recommends behavioral therapy alone.

In any case, doctors "should ask all patients whether they smoke, and provide appropriate interventions to help smokers quit," task force member Francisco Garcia, M.D., M.P.H., said in a USPSTF news release. "We're fortunate that doctors and patients have a choice of many interventions that have been proven to be effective," he said. The task force will accept public comment on its recommendations until June 1.

Evidence Review
Draft Recommendation
Comment on Recommendation

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs